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Abstract 
Diffuse large B-cell lymphoma is the most common form of lymphoma. It usually begins 
in the lymph nodes; up to 40% may have an extranodal presentation. According to a 
definition of primary extranodal lymphoma with presentation only in extranodal sites, 
there are reports of large B-cell lymphomas limited to liver or spleen as separate entities, 
and to date there have been only three documented cases of primary hepatosplenic 
presentation. This paper reports a fourth case. Due to a review of the literature and the 
clinical course of the case reported, we conclude that primary hepatosplenic large B-cell 
lymphoma has been found predominantly in females older than 60 years. The patients 
reported had <2 months of evolution prior to diagnosis, prominent B symptoms, 
splenomegaly in three and hepatomegaly in two, none with lymph node involvement. All 
had thrombocytopenia and abnormal liver function tests; three had anemia and elevated 
serum lactic dehydrogenase levels, two with hemophagocytosis in bone marrow. 
Because of the previously mentioned data, it can be stated that primary hepatosplenic 
lymphoma is an uncommon and aggressive form of disease that requires immediate 
recognition and treatment. 
 
Introduction 
Non-Hodgkin lymphomas (NHL) are a heterogeneous group of lymphoproliferative 
diseases. Their ontogeny is related with the process of maturation in the lymphoid nodal 
tissue. Thus, their clinical manifestations generally begin in nodal areas, but in up to 40% 
presentation can be primarily extranodal, and clinical behavior may be variable according 
to the organs and tissues initially involved, sometimes rendering their diagnosis difficult 
[1, 2].  
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Primary hepatosplenic presentation has been reported among extranodal forms of 
NHL; a rare entity, its presence is limited to case reports, the majority of T-cell origin [3]. 
To date, only three cases of primary hepatosplenic large B-cell lymphoma have been 
reported, two of these associated with hemophagocytic syndrome (HS) in bone marrow 
(BM) [4–6]. 
We report a new patient with primary hepatosplenic diffuse large B-cell lymphoma 
(DLBCL) as well as HS in BM. Due to the rarity of the condition, its morphologic and 
phenotypic characteristics, but principally because of the particularly severe clinical 
manifestations of this case and the patients previously reported, we consider it of interest 
to review the information regarding all these patients. 
Case Report 
A female, 67 years of age, was diagnosed due to anemia in May 2004 with refractory anemia with 
multilineage dysplasia, and received treatment with folic acid and vitamin B12. In July 2004 the patient 
complained of night fever up to 104.0°F, night sweats, and a 13.23 lb weight loss, and received 
antimicrobial therapy without improvement. In August 2004 she was hospitalized for fever of unknown 
origin. 
At physical examination, she was conscious, cooperative, and with important wasting. Her weight 
was 116.85 lb, height 5.1181 ft, blood pressure 105/70 mm Hg, pulse 80/min, respiratory rate 18/min, 
and temperature 101.3°F. It is important to mention that the patient presented no adenomegalies, 
visceromegalies, bone pain, purpura, bleeding, or infectious source. 
The laboratory reported the following: hemoglobin (Hb) 11.9 g/dl; hematocrit (Ht) 34%; mean 
corpuscular volume 108 fl; mean corpuscular Hb 34.5 pg; leukocytes 9.2 × 10
9/l, with neutrophils 7.0 × 
10
9/l and lymphocytes 0.6 × 10
9/l; platelets 74 × 10
9/l; erythrocyte sedimentation rate 52 mm/h; blood 
glucose 118 mg/dl; urea nitrogen 18 mg/dl; creatinine 0.9 mg/dl; Na 129 mEq/l, K 4.0 mEq/l; Cl 100 
mEq/l; total protein 5.2 g/l, with albumin 2.9 g/l and globulin 2.3 g/l. In addition, ALT was 139 IU/l, 
AST 91 IU/l, and alkaline phosphatase 304 IU/l, lactic dehydrogenase 1,089 IU/l (normal range 101–208 
IU/l), and β-2 microglobulin 5,825 ng/dl (normal range 700- 3,400 ng/dl). 
Computed tomography (CT) of the abdomen and pelvis showed hepatosplenomegaly and thorax 
was normal, both without evidence of adenopathies. Gallium
67 scan confirmed visceral enlargement but 
found no lymph node enlargement or focal uptake in liver, spleen, lymph nodes or other sites. Cultures 
at different sites were negative, as well as the serological test for hepatitis B and C, cytomegalovirus, 
human immunodeficiency, and Epstein-Barr virus. Febrile reactions and VDRL tests were negative. BM 
aspiration and biopsy showed hemophagocytosis of erythrocytes and platelets (fig. 1) and 
myelodysplastic syndrome abnormalities. 
The patient deteriorated rapidly, and within a few days experienced severe falls in Hb to 8.4 g/dl, Ht 
to 27%, and platelets to 29 × 10
9/l. Therefore, an exploratory laparotomy was performed on September 
3, 2004, finding hepatosplenomegaly but no evidence of adenomegalies; splenectomy and wedge liver 
biopsies were conducted. The spleen weighed 1.82 lb, and like the liver biopsy was infiltrated by large 
lymphoma cells, CD20 positive, with focal positivity for BCL-2 and Ki-67 in 60% of cells. 
Postoperatively, the patient developed Escherichia coli-associated gastroenteritis and at the same 
time basal pneumonia in left lung with blood cultures positive for coagulase-negative staphylococci. She 
received antimicrobial therapy with rapid improvement of her clinical condition, allowing us to begin 
chemotherapy with cyclophosphamide-mitoxantrone-vincristine-prednisone plus rituximab (CNOP-R) 
for a total of eight cycles. The patient showed remarkable improvement, and from the third cycle on, we 
observed a steady rise in Hb and Ht; leukocytes and platelets increased to normal levels, and lactic 
dehydrogenase and β-2 microglobulin decreased to normal values. Complete response was achieved and 
has been sustained until the date of this report. Positron emission tomography-CT scan carried out in 
July 2007 showed no evidence of disease.  
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Discussion 
With regard to this review, one controversial issue comprises the definition of 
‘extranodal lymphoma’. While some authors consider this diagnosis only when a 
complete set of studies demonstrates lymphoma activity in a single extranodal site, others 
describe that an ‘extranodal lymphoma’ can be considered when the main signs-and-
symptoms-related component of the disease is localized in extranodal territory, although 
minimal nodal compromise coexists. Certain authors have also proposed that extranodal 
lymphoma can be considered when at least 75% of the disease is localized in an extranodal 
area. In this paper, we preferred the first concept [1]. 
Thus, according to the definition we chose, we found four cases of primary 
hepatosplenic DLBCL on reviewing the literature [8–10]; however, we rejected the case 
reported by Gil et al. because in addition to hepatosplenic infiltration, the patient had 
lymphoma in BM and bones [7]. The remanining three cases reviewed [4–6] only 
presented hepatosplenic infiltration (table 1). 
As we previously mentioned, NHL primarily affect lymphoid node tissue; nonetheless, 
between 24 and 37% can have primary extranodal manifestations. The most frequently 
affected extranodal sites include the following: gastrointestinal tract (mainly stomach), 
24%; Waldeyer’s ring, 19%; soft tissues, 19%; testis, 4%; skin, 3.8%; bone, 3.7% [1, 2]. 
Although there are several reports of cases of hepatic or splenic primary lymphomas as 
separate entities, primary hepatosplenic lymphomas represent a rare entity, and the 
majority of cases reported have been of T-cell origin, especially the γ/δ subtype [3], 
although the presentation of primary hepatosplenic DLBCL is limited to the four cases 
analyzed in this paper (tables 1 and 2) [4–6], including our own case. Considering the 
small number of patients, it is not possible to establish definitive conclusions. 
Nevertheless, this review allows us to underscore their principal characteristics, such as 
limited disease localization and the severe clinical manifestations of this rare 
hepatosplenic tumor. These manifestations included that three of the four patients were 
>60 years of age and three were females. All cases had B symptoms and none had lymph 
node or other sites of involvement. Three patients had splenomegaly and only two liver 
enlargement, although all cases had liver function tests abnormalities. The CT and 
gallium scans showed hepatosplenomegaly in two and isolated splenomegaly in one 
patient, with focal lesions in patient 1 (table 2). All patients had thrombocytopenia, and 
three had anemia, these cytopenias being related with lymphoma, splenomegaly, and in 
two cases with HS. 
The disease’s clinical course was rapid and aggressive; in two cases, it was fatal in a 
short period of time. It is noteworthy that our patient had a rapid clinical deterioration 
with fever, visceromegalies, and a dramatic fall in the pre-existing cytopenias within a few 
days (table 1) as evidence of disease severity. 
The association of NHL with HS has been reported in those of T-cell origin; in relation 
with B-cell lymphomas, this association has been occasionally found in the subtypes T-
cell-rich LBCL and angiotrophic lymphoma [8, 9]. Its pathogenesis has been attributed in 
some cases to the use of granulocyte macrophage colony stimulating factor, and in some 
others the release of some endogenous factor released by T-cells that stimulate 
macrophage proliferation and function has also been implicated [10–12]. In certain 
patients HS appears in relation to viral infections, but neither of the two patients with HS 
in this report (table 1) had evidence of such an infection type.  
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It is considered that increased frequency of lymphomas in general and hepatic or 
splenic LBCL is related to hepatitis C infection [8, 9]. Gil et al. reported a young patient 
with hepatitis C viral infection who developed an aggressive lymphoma with hepatic, 
splenic, nodal, bone, and BM infiltration with a fatal outcome within a few days [7]. Two 
of the cases analyzed (cases 1 and 3) (table 2) had a similar course and both had positive 
serology for hepatitis C virus. The exact mechanism responsible for the association 
between hepatitis C virus and such an aggressive lymphoma is partially unknown [6, 7]. 
Finally, only the two patients who received complete schemes of chemotherapy were 
able to survive (patients 2 and 4) to the acute phase of the lymphoma, with prolonged 
survival (table 2). 
In conclusion, we report the fourth clearly documented case of primary hepatosplenic 
DLBCL associated with HS. According to the findings of the present review, it is evident 
that this rare entity tends to appear in females and in individuals of advanced age. It is 
characterized by severe signs and symptoms, rapid evolution of cytopenias 
(thrombocytopenia and anemia), abnormalities of liver function tests, and follows a rapid 
and aggressive, even fatal, clinical evolution. 
Consequently, adequate treatment of this disease requires early histologic and 
immunophenotypic diagnosis. Thus, it is necessary to have this rare variety of lymphoma 
in mind in patients presenting the characteristics described herein. 
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Table 1. Clinical and laboratory findings in four patients with primary hepatosplenic large 
B-cell lymphoma 
Clinical case  01  00.2  00.3  00.Present case 
Gender  00F  000.F  00.M  000.F 
Age, years  074  00.41  00.75  00.67 
Evolution, months  002  000.1  000.2  000.2 
B symptoms  00+  000.+  000.+  000.+ 
Splenomegaly  00+  000.+  000.–  000.+ 
Hepatomegaly  00+  000.–  000.–  000.+ 
Adenomegalies  00–  000.–  000.–  000.– 
Blood cell cytology         
Hemoglobin, g/dl  .9.8  007.1  014.1  008.4 
Leukocytes, × 10
9/l  .4.5  006.1  008.7  004.9 
Platelets, × 10
9/l  070  000.4  00.81  00.29 
Liver function test          
AST, IU/dl  080  0.163  0.134  00.91 
ALT, IU/dl  115  00.42  00.64  0.139 
AP, IU/dl  324  0.575 2,502 0.304 
GGT, IU/dl  420  00NA  0.482  0.400 
LDH,  IU/l  NA  1,948 1,805 1,089 
β-2 microglobulin, ng/ml  NA  003.5  00NA 5,825 
Viral  serology      
HCV  00+  000.–  000.+  000.– 
HBV  00–  000.–  000.–  000.– 
CMV  00–  000.–  000.–  000.– 
HIV  00–  000.–  000.–  000.– 
EBV  00–  000.–  000.–  000.– 
Febrile reactions  NA  00NA  00NA  000.– 
F = Female; M = male; + = present; – = absent; NA = not available; LDH = lactic 
dehydrogenase; HCV = hepatitis C virus; HBV = hepatitis B virus; CMV = cytomegalovirus; 
HIV = human immunodeficiency virus; EBV = Epstein-Barr virus. 
 
 
Table 2. Imaging and histopathologic studies and treatment 
Case   1  2  3  Present case 
Computed tomography  liver: 4 nodes  –  hepatomegaly  hepatomegaly 
  spleen: 1 node  splenomegaly/  splenomegaly  splenomegaly 
 ascitis  infarction     
Gallium
67  liver and spleen positive  ND  ND  negative 
Bone marrow  negative  HS  negative  HS 
Immunohistologic  liver biopsy:  splenectomy and  liver and splenic  splenectomy and 
findings  LBCL, cirrhosis  liver biopsy: LBCL  biopsy: LBCL  liver biopsy: LBCL 
Treatment chemotherapy  chemotherapy  no  chemotherapy 
  1 cycle  6 cycles    8 cycles 
Liver status  fulminant death  alive  death caused by  alive 
     fulminant  hepatitis   
ND = Not done; HS = hemophagocytosis; LBCL = large B-cell lymphoma.  
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Fig. 1. Bone marrow aspiration. Macrophage with phagocytosis of erythrocytes and platelets 
(hemophagocytosis). 
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